SHANDONG XINHUA Secures Drug Registration Certificate for Glucosamine Sulfate Capsules

Stock News02-09 16:38

SHANDONG XINHUA (00719) has announced that it recently obtained the Drug Registration Certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration. In August 2024, the company submitted the application materials for the market approval registration of the capsules to the Center for Drug Evaluation (CDE) of the NMPA, which were accepted. The registration certificate was granted in February 2026, with the review conclusion being approval for registration. This product is clinically indicated for the treatment of primary and secondary osteoarthritis. It is classified as a Category B drug in the National Reimbursement Drug List for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance (2025). According to relevant statistics, the sales of Glucosamine Sulfate Capsules in Chinese public medical institutions reached approximately RMB 850 million in 2024.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1154803723?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-09 16:38","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1154803723","market":"us","top_or_hot":-1,"title":"SHANDONG XINHUA Secures Drug Registration Certificate for Glucosamine Sulfate Capsules","media":"Stock News","content":"<p>SHANDONG XINHUA (00719) has announced that it recently obtained the Drug Registration Certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration. In August 2024, the company submitted the application materials for the market approval registration of the capsules to the Center for Drug Evaluation (CDE) of the NMPA, which were accepted. The registration certificate was granted in February 2026, with the review conclusion being approval for registration. This product is clinically indicated for the treatment of primary and secondary osteoarthritis. It is classified as a Category B drug in the National Reimbursement Drug List for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance (2025). According to relevant statistics, the sales of Glucosamine Sulfate Capsules in Chinese public medical institutions reached approximately RMB 850 million in 2024.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SHANDONG XINHUA Secures Drug Registration Certificate for Glucosamine Sulfate Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSHANDONG XINHUA Secures Drug Registration Certificate for Glucosamine Sulfate Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-02-09 16:38</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SHANDONG XINHUA (00719) has announced that it recently obtained the Drug Registration Certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration. In August 2024, the company submitted the application materials for the market approval registration of the capsules to the Center for Drug Evaluation (CDE) of the NMPA, which were accepted. The registration certificate was granted in February 2026, with the review conclusion being approval for registration. This product is clinically indicated for the treatment of primary and secondary osteoarthritis. It is classified as a Category B drug in the National Reimbursement Drug List for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance (2025). According to relevant statistics, the sales of Glucosamine Sulfate Capsules in Chinese public medical institutions reached approximately RMB 850 million in 2024.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1154803723","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1154803723","pubTimestamp":1770626302,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SHANDONG XINHUA (00719) has announced that it recently obtained the Drug Registration Certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration. In August 2024,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","00719":"山东新华制药股份","BK1191":"制药"},"translate_title":"山东新华获得硫酸氨基葡萄糖胶囊药品注册证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00719":1},"content_text":"SHANDONG XINHUA (00719) has announced that it recently obtained the Drug Registration Certificate for Glucosamine Sulfate Capsules from the National Medical Products Administration. In August 2024, the company submitted the application materials for the market approval registration of the capsules to the Center for Drug Evaluation (CDE) of the NMPA, which were accepted. The registration certificate was granted in February 2026, with the review conclusion being approval for registration. This product is clinically indicated for the treatment of primary and secondary osteoarthritis. It is classified as a Category B drug in the National Reimbursement Drug List for Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance (2025). According to relevant statistics, the sales of Glucosamine Sulfate Capsules in Chinese public medical institutions reached approximately RMB 850 million in 2024.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1154803723","isCrawlerRequest":true}